Navigation Links
CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
Date:1/4/2008

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the publication of a European study of atrial fibrillation patients treated with CryoCor's Cardiac Cryoablation System. The purpose of the study was to evaluate the role of atrial flutter in the recurrence of atrial fibrillation and the effectiveness of an ablation strategy focused on isolating the pulmonary veins to treat the atrial fibrillation. The study was published in the December 11, 2007 issue of Circulation.

The 98-patient study was conducted by Dr. Wendel Moreira, Dr. Luz-Maria Rodriguez, Dr. Carl Timmermans and others in Academic Hospital Maastricht using CryoCor's Cardiac Cryoablation System. The study prospectively evaluated the best catheter ablation strategy in patients with paroxysmal atrial fibrillation with and without concomitant right atrial flutter. During follow-up averaging 26 months, the authors found that electrical isolation of the pulmonary veins by catheter ablation was successful in patients without concomitant atrial flutter at an 82% success rate. In patients with concomitant atrial flutter, the combination of ablation for atrial flutter and pulmonary vein isolation alone to treat atrial fibrillation was frequently insufficient in preventing recurrences of atrial fibrillation (recurrence rate of 67%). The authors concluded that those patients with atrial flutter and atrial fibrillation may require additional sites of ablation to effectively treat their atrial fibrillation.

Dr. Rodriguez, senior author of the study, stated, "This is the first time that an ablation strategy for paroxysmal atrial filbrillation and atrial flutter has been systematically studied. This has implications for the tools that a clinician may use to treat these atrial arrhythmias. Based on this study, we do not believe that it will be sufficient to simply isolate the pulmonary veins in a significant proportion of patients."

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the study's results and conclusions drawn from the study's results, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology and the diagnosis and treatment of atrial arrhythmias; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

Contact:

CryoCor, Inc.

Gregory J. Tibbitts

Chief Financial Officer

(858) 909-2200

gtibbitts@cryocor.com

The Ruth Group

Nick Laudico / Zack Kubow (investors)

(646) 536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCor Files Response to Patent Infringement Lawsuit
2. CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
3. CryoCor Appoints New Vice President of Sales and Marketing
4. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
5. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
6. FDA Reports New Risks Posed by Anemia Drugs
7. Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement
8. UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007
9. The Ensign Group, Inc. Reports Third Quarter 2007 Earnings
10. HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million
11. Par Pharmaceutical Reports Third-Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... Aimed at nurses and employees in the health care world, this installment ... nursing and health care industry. It also provides insight to the developing trends and ... As the nursing industry is coming out of one of the biggest recessions in ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... ... 26, 2016 , ... Cabot Corporation, Pfizer, and 3M are ... court documents and SEC filings. A jury has returned a verdict of ... Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million ...
(Date:5/26/2016)... ... 26, 2016 , ... Georgia State University College of Law ... , Answering to the increasing demand for curricular specializations, the Certificate in Intellectual ... and land use law. ,  , “The demand for lawyers with specific knowledge ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... -- According to the 2016 report, a ... blood pressure monitoring system market growth. With aging, the ... respond to different pressure rates, leading to hypertension or ... cardiovascular disorders such as heart failure, stroke, coronary artery ... in prevalence each year. WHO estimates that 17 million ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology: